Skip to main content
SpringerLink
Log in

Zur Behandlung schizophrener Negativsymptome mit neuen Dopaminagonisten

  • Conference paper
Biologische Psychiatrie der Gegenwart

Zusammenfassung

Die Wirksamkeit der Neuroleptika auf akute psychotische Symptome wird auf deren Fähigkeit zur Blockade postsynaptischer Dopaminrezeptoren vom D2- bzw. D3-Typ zurückgeführt. Hingegen sprechen schizophrene Negativsymptome, die in vielen Fällen das akute Krankheitsgeschehen überdauern, oftmals nur schlecht auf klassische Neuroleptika an. Die „Dopaminhypothese der Schizophrenie“erklärt produktive psychotische Symptome mit einer funktionellen dopaminergen Überaktivität bzw. einer gesteigerten postsynayptischen Rezeptorhypersensitivität. Hingegen gibt es zur Erklärung schizophrener Negativsymptome kein allgemein akzeptiertes Erklärungsmodell. Diskutiert wurden u. a. eine Dysfunktion des noradrenergen Reward-Systems [24], das serotonerge System [3] oder eine gesteigerte cholinerge (muskarinische) Überaktivität [25].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Angrist B, Sathananthan J, Gershon S (1973) Behavioural effects of L-dopa in Schizophrenie patients. Psychopharmacologia 31: 1–12

    Article  PubMed  CAS  Google Scholar 

  2. Asano T, Noma T, Matsude K, Ikeda H, Otsuki S (1973) Effects of L-dopa on the hypo- chondriac complaints of chronic psychotics (in Japanese). Clin Psychiatry 15: 745–51

    Google Scholar 

  3. Bleich A, Brown SL, Kahn R, van Praag HM (1988) The role of serotonin in schizophrenia. Schizophr Bull 14: 297–315

    Article  PubMed  CAS  Google Scholar 

  4. Buchanan FH, Parton RV, Warren JW (1975) Double-blind trial of L-dopa in chronic schizophrenia. Aust NZ J Psychiatry 9: 269–71

    Article  CAS  Google Scholar 

  5. Calil HM, Yesuage JA, Hollister LE (1971) Low dose levodopa in schizophrenia. Commun Psychopharmacol 1: 593–6

    Google Scholar 

  6. Carpenter WT Jr, Heinrichs DW, Alphs LD (1985) Treatment of negative symptoms. Schizophr Bull 11: 440–52

    Article  PubMed  Google Scholar 

  7. Crow TJ (1980) Molecular pathology of schizophrenia: more than one disease process? Br Med J 280: 1–9

    Article  Google Scholar 

  8. Filip V, Marsalek M, Halkova E, Karen P (1992) Treatment of extrapyramidal side effects with terguride. Psychiatry Res 41: 9–16

    Article  PubMed  CAS  Google Scholar 

  9. Friedhoff AJ (1988) Dopamine as a mediator of a central stabilizing system. Neuro- psychopharmacology 3: 189–91

    Article  Google Scholar 

  10. Garfinkel PE, Stancer HC (1976) L-dopa and schizophrenia. Can Psychiatr Assoc J 21: 27–9

    PubMed  CAS  Google Scholar 

  11. Gerbaldo H, Demisch L, Lehmann C-O, BochnikJ (1988) The effect of OPC-4392, a partial dopamine receptor agonist on negative symptoms: results of an open study. Pharmacopsychiatry 21: 387–8

    CAS  Google Scholar 

  12. Gerlach J, Luhdorf K (1975) The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs. Psychopharmacology 44: 105–10

    Article  CAS  Google Scholar 

  13. Gründer G, Wetzel H, Hillert A, Benkert O (1992) Roxindole, a dopamine D2 auto- receptor agonist, in the treatment of negative symptoms of schizophrenia [Abstr]. Pharmacopsychiatry 25: 102

    Google Scholar 

  14. Inanaga K, Inouee K, Tachibana H, Oshima M, Kotorii T (1972) Effect of L-dopa in schizophrenia. Folia Psychiatr Neurol Jpn 26: 145–57

    PubMed  CAS  Google Scholar 

  15. Inanaga K, Nakasawa T, Inouee K, Tachibana H, Oshima M, Kotorii T, Tanaka M, Ogawa N (1975) Double-blind controlled study of L-dopa therapy in schizophrenia. Folia Psychiatr Neurol Jpn 29: 123–43

    PubMed  CAS  Google Scholar 

  16. Inanaga K, Kuniyoshi M (1991) Different responsiveness of negative symptoms to pharmacotherapy. In: Racagni, et al (eds) Biological psychiatry, vol 1. Elsevier, New York Amsterdam London, pp 461–3

    Google Scholar 

  17. Kay SR, Opler LA (1985) L-dopa in the treatment of negative schizophrenic symptoms: a single-subject experimental study. Int J Psychiatr Med 15: 293–98

    Article  Google Scholar 

  18. Klimke A, Klieser E (1991) The antipsychotic efficacy of the dopaminergic autore- ceptor agonist EMD 49980 (Roxindol) - results of an open clinical study. Pharmacopsychiatry 24: 107–112

    Article  PubMed  CAS  Google Scholar 

  19. Klimke A, Klieser E (1991) The treatment of positive and negative schizophrenic symptoms with dopamine agonists. In: Marneros A, Andreasen NC, Tsuang MT (eds) Negative versus positive schizophrenia. Springer, Berlin Heidelberg New York Tokyo, pp 377–398

    Chapter  Google Scholar 

  20. Levi-Minzi S, Bermanzohn PC, Siris SG (1991) Bromocriptine for „negative“schizophrenia. Compr Psychiatry 32: 210–6

    Article  PubMed  CAS  Google Scholar 

  21. Ogura C, Kishimato H, Nakao T (1976) Clinical effects of L-dopa on schizophrenia. Curr Ther Res 20: 308–18

    PubMed  CAS  Google Scholar 

  22. Otsuka T, Kumashiro E, Mizushima S, Maruko K, Koizumi S, Unno K (1974) The effect of L-dopa on schizophrenia (in Japanese). Jpn J Clin Psychiatry 3: 629–37

    Google Scholar 

  23. Sarai K, Kimura N, Ishi T, Iseki K, Imada H, Kawamura T, Kino M, Echigo T (1973) Possibility of amine precursor-therapy of schizophrenia by experimental study of L-dopa (inJapanese). Clin Psychiatry 15: 189–96

    Google Scholar 

  24. Stein L, Wise CD (1971) Possible etiology of schizophrenia: progressive damage to the noradrenergic reward system by 6-hydroxy-dopamine. Science 171: 1032–6

    Article  PubMed  CAS  Google Scholar 

  25. Tandon R, Greden JF (1989) Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia. Arch Gen Psychiatry 43: 398–402

    Google Scholar 

  26. Wells B, et al (1991) Bromocriptine in schizophrenia. Pharmacopsychiatry 24: 113–7

    Article  Google Scholar 

  27. Wiedemann K, Benkert O, Holsboer F (1990) B-HT 920 - a novel dopamine autore-ceptor agonist in the treatment of patients with schizophrenia. Pharmacopsychiatry 23: 50–5

    Article  PubMed  CAS  Google Scholar 

  28. Wiedemann K, Loycke A, Krieg JC, Holsboer F (1992) Novel dopamine autoreceptor agonists B-HT 920 and EMD 49980 in the treatment of patients with schizophrenia. Pharmacopsychiatry 25: 92 [Abstr]

    Google Scholar 

  29. Yamauchi I (1972) The effect of L-dopa on schizophrenia. Clin Psychiatry 14: 941–9

    Google Scholar 

  30. Yaryura-TobiasJA, Diamond B, Merlis S (1970) The action of L-dopa on schizophrenic patients (a preliminary report). Curr Ther Res 12: 528–31

    Google Scholar 

  31. Yaryura-TobiasJA, Wolpert A, Dand L, Merlis S (1970) Action of L-dopa in drug- induced extrapyramidalism. Dis Nerv Syst 31: 60–3

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Psychiatrische Klinik, Heinrich-Heine-Universität, Bergische Landstraße 2, D-40629, Düsseldorf, Bundesrepublik Deutschland

    Dr. A. Klimke, E. Klieser & B. Schmitz

Authors
  1. Dr. A. Klimke
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Klieser
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B. Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Département Universitaire de Psychiatrie Adultes (DUPA), Route de Cery, CH-1008, Prilly-Lausanne, Switzerland

    Pierre Baumann

Rights and permissions

Reprints and permissions

Copyright information

© 1993 Springer-Verlag Wien

About this paper

Cite this paper

Klimke, A., Klieser, E., Schmitz, B. (1993). Zur Behandlung schizophrener Negativsymptome mit neuen Dopaminagonisten. In: Baumann, P. (eds) Biologische Psychiatrie der Gegenwart. Springer, Vienna. https://doi.org/10.1007/978-3-7091-9263-4_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-9263-4_27

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-7091-9264-1

  • Online ISBN: 978-3-7091-9263-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation